Relutrigine

Name: Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Generic, brand name and therapeutic class of product
Published: 2026-09-14T15:39:06-04:00

SCN2A- and SCN8A-related developmental and epileptic encephalopathies

Manufacturer: Praxis Precision Medicines
Regulatory submission: NDA submitted in early 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Generic, brand name and therapeutic class of product

3 evidence topics · 3 sources

Manufacturer: Praxis Precision Medicines

Field	Quoted record
Sponsor	“Praxis Precision Medicines, Inc.”

Product names

“Relutrigine (PRAX-562)” (opens the source at this quote in a new tab)

Drug class

“a sodium channel functional state modulator for pediatric use” (opens the source at this quote in a new tab)